The U.S. Food and Drug Administration has approved pimicotinib (Pimjetmi) for adults with symptomatic tenosynovial giant cell tumor (TGCT) when surgery could worsen function or cause serious complications. The November 10 decision creates a new systemic treatment option for a rare tumor that develops in the tissues surrounding joints.
What TGCT is
TGCT arises from the synovium, tendon sheath or bursa. It is generally not described as a typical metastatic cancer, but it can grow locally, damage a joint and cause pain, swelling, stiffness and loss of movement. Surgery remains important for many patients. The FDA indication is narrower: it concerns adults with symptoms whose operation may itself create greater functional limitation or serious morbidity.
That distinction matters. An approval does not mean every person with TGCT should receive the medicine, and it does not replace evaluation by a specialist team. Tumor location, symptoms, expected surgical outcome, other conditions and the patient’s priorities all shape the decision.
What the pivotal trial found
The FDA based its decision on MANEUVER, an international, double-blind, randomized placebo-controlled study. Participants had confirmed symptomatic TGCT, measurable disease and a situation in which surgery could cause dysfunction or serious complications. They were assigned in a 2:1 ratio to pimicotinib 50 mg once daily or placebo.
At week 25, the overall response rate assessed by an independent central review was 56% with pimicotinib and 3.2% with placebo. The median duration of response had not been reached at the time of analysis. Among responders, 91% had a response lasting at least six months and 77% at least 12 months.
The trial also assessed outcomes that can be especially meaningful in a joint disorder. The FDA reported statistically significant improvements in active range of motion, worst pain and physical functioning compared with placebo. These findings help connect tumor response with day-to-day function, although longer follow-up remains important.
Safety still needs close monitoring
The most common adverse reactions, occurring in more than 20% of treated patients, included itching, rash, facial or periorbital swelling, fatigue, nausea, headache and peripheral swelling. Common laboratory changes included rises in creatine phosphokinase, liver enzymes, lipase, cholesterol and other markers.
The prescribing information includes warnings and precautions for liver toxicity, embryo-fetal toxicity and increased serum creatinine without an apparent effect on kidney function. These risks make baseline assessment, laboratory monitoring and review of new symptoms essential parts of care. People should not start, stop or change any cancer medicine without the clinician who knows their diagnosis and full medical history.
A U.S. approval is not a global authorization
The review took place through Project Orbis, an FDA framework that supports coordinated review with regulators in other countries. Australia, Canada, Israel, Switzerland and the United Kingdom participated, while the European Medicines Agency was an official observer. Each regulator still makes its own decision, so the FDA action should not be interpreted as an automatic approval in Europe or elsewhere.
Questions patients can bring to an appointment
- Is surgery expected to preserve function, or could it create substantial disability?
- How were the diagnosis and measurable disease confirmed?
- What treatment goal matters most: pain relief, movement, tumor shrinkage or delaying surgery?
- Which side effects and laboratory changes require urgent contact?
- How often will imaging, joint function and blood tests be reviewed?
For people living with a rare joint tumor, the FDA decision broadens the conversation beyond a simple choice between surgery and observation. The practical value of pimicotinib will depend on careful patient selection, monitoring and longer-term evidence.
Primary source: U.S. Food and Drug Administration, November 10, 2026.
